בשל "הגנת זכויות יוצרים" מובא להלן קישור לתקציר המאמר. לקריאתו בטקסט מלא, אנא פנה/י לספרייה הרפואית הזמינה לך. 

Patients with hormone receptor-positive breast tumors receive hormonal therapy with either selective estrogen receptor modulators (SERMs) (eg, tamoxifen) or aromatase inhibitors (AIs) (eg, anastrozole) for 5 to 10 years.

Patients are using these therapies frequently during breast reconstruction.

Literature investigating the effects of hormonal modulators on breast reconstruction outcomes demonstrates conflicting results.

We sought to perform a systematic evaluation to assess the effects of hormonal therapy on breast reconstruction outcomes and to guide perioperative management of antiestrogen therapies.

A MEDLINE, PubMed, and EBSCO Host search of articles regarding the effects of SERMs and AIs on breast reconstruction was performed.

Outcomes evaluated included wound complications, total or partial flap loss, and thromboembolic events.

Included studies were assigned Methodological Index for Nonrandomized Studies quality scores.